The EGFR (previously known as HER1), Epidermal Growth Factor Receptor, gene on chromosome band 7p11.2, is a type 1 tyrosine kinase receptor for members of the epidermal growth factor family. Binding of the EGFR and epidermal growth factor proteins leads to cell proliferation1.
Abnormally elevated EGFR kinase activity can lead to proliferative diseases such as non-small-cell lung carcinoma (NSCLC), which accounts for 80-85% of all lung cancers2, and less frequently breast cancer3, amongst others.
There are three small molecule EGFR kinase inhibitor drugs in clinical use (gefitinib, erlotinib and lapatinib) and several others that are currently undergoing clinical development4. Approximately 10% of lung cancer patients show a rapid and dramatic response to these Tyrosine Kinase Inhibitors (TKIs)5,6.
FISH has proven to be useful for determining the amplification status of EGFR in NSCLC and has therefore aided in the selection of patients for treatment with EGFR TKIs7.
It was very important for us to have more consistent results with our probes — easy-to-read bright signals and a range of vial sizes, which is much more cost-effective. It also was critical to upgrade our pretreatment kit to expedite the analysis of FFPE samples. We can now complete the process in about 90 minutes. Janet M. Cowan, PhD, Director of the Cytogenetics Laboratory at Tufts Medical Center
1. Voldborg et al., Annals of Oncology 8: 1197-1206,1997
2. Jemal A et al., CA Cancer J Clin 2006;56:106-30
3. Bhargava R et al., Modern Path 2005;18:1027-33
4. Hegymegi-Barakonyi B, Curr Opin Mol Ther 2009;11(3):308-21
5. Lynch TJ et al., N E J Med 2004;350:2129-39
6. Pao W et al., Proc Natl Acad Sci USA 2004;101(36):13306-11
7. Hirsch FR et al., JCO 2008;26(20): 3351-7
- Area of Interest*
- Breast Cancer, Colorectal Cancer, Lung Cancer
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.